Review highlights TIGIT as a promising second-generation immunotherapy target

[News]

Malignant tumors remain a major threat to human health, with conventional therapies and first-generation immune checkpoint inhibitors (ICIs) facing limitations like drug resistance and low response rates.

More... (https://www.news-medical.net/news/20260605/Review-highlights-TIGIT-as-a-promising-second-generation-immunotherapy-target.aspx)